Entering text into the input field will update the search result below

Alexion teams up with Complement Pharma to develop C6 complement inhibitor

  • Alexion Pharmaceuticals (NASDAQ:ALXN -0.2%) has agreed to co-develop CP010, a C6 complement inhibitor for the potential treatment of neurodegenerative disorders, with privately held Amsterdam-based Complement Pharma.
  • Under the terms of the partnership, Alexion will provide Complement with up to €14M in milestone payments through Phase 1b development. Alexion has the option to acquire Complement during the term of the agreement.

Recommended For You

Related Stocks

SymbolLast Price% Chg
ALXN--
Alexion Pharmaceuticals, Inc.